Patent intelligence · EP
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR B…
Patent details — EP 1303278
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Apr 23, 2003
- Expiration
- Apr 18, 2023
- Applicant
- NEUROBIOTEC GMBH [DE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 10 A I, A61K 9/ 20 A I
Quick answer
EP 1303278 (KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted Apr 23, 2003. Expires Apr 18, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NEUROBIOTEC GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 9/ 10 A I, A61K 9/ 20 A I, A61K 9/ 70 A I, A61K 31/ 13 A I
More from NEUROBIOTEC GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
granted -
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
IT MI20070164
CEROTTO TRANSDERMICO
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
DE 10341317
Mittel zur transdermalen Applikation
expired -
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
expired -
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
expired
Frequently asked questions
What is US patent 1303278?
EP 1303278 (KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN) is held by NEUROBIOTEC GMBH [DE]. Status: expired. Granted Apr 23, 2003. Expires Apr 18, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1303278?
NEUROBIOTEC GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does EP 1303278 expire?
Our index shows an expiration date of Apr 18, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.